ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000C66

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

Identifieur interne : 000C66 ( PascalFrancis/Corpus ); précédent : 000C65; suivant : 000C67

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

Auteurs : ABDALLAH HADJ TAHAR ; Laurent Gregoire ; Evelyne Bangassoro ; Paul J. Bedard

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 2000.

RBID : Pascal:00-0500117

Descripteurs français

Pascal (Inist)
- Lévodopa, Antiparkinsonien, Parkinson maladie, Dyskinésie, Toxicité, Cabergoline, Stimulant dopaminergique, Récepteur dopaminergique D2, Agoniste, Traitement, Chimiothérapie, Activité biologique, Long terme, Relation dose réponse, Animal, Ergot dérivé, Singe, Voie souscutanée.

English descriptors

KwdEn :
- Agonist, Animal, Antiparkinson agent, Biological activity, Cabergoline, Chemotherapy, D2 Dopamine receptor, Dopamine agonist, Dose activity relation, Dyskinesia, Ergot derivatives, Levodopa, Long term, Monkey, Parkinson disease, Subcutaneous administration, Toxicity, Treatment.

Abstract

The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D₂-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D₂ receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0362-5664`
A02	`01`			`@0 CLNEDB`
A03		`1`		`@0 Clin. neuropharmacol.`
A05				`@2 23`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys`
A11	`01`	`1`		`@1 ABDALLAH HADJ TAHAR`
A11	`02`	`1`		`@1 GREGOIRE (Laurent)`
A11	`03`	`1`		`@1 BANGASSORO (Evelyne)`
A11	`04`	`1`		`@1 BEDARD (Paul J.)`
A14	`01`			`@1 Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center @2 Ste-Foy, Québec @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 195-202`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16720 @5 354000091364260050`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 76 ref.`
A47	`01`	`1`		`@0 00-0500117`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical neuropharmacology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D₂-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D₂ receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Lévodopa @5 01`
C03	`01`	`X`	`ENG`	`@0 Levodopa @5 01`
C03	`01`	`X`	`SPA`	`@0 Levodopa @5 01`
C03	`02`	`X`	`FRE`	`@0 Antiparkinsonien @5 04`
C03	`02`	`X`	`ENG`	`@0 Antiparkinson agent @5 04`
C03	`02`	`X`	`SPA`	`@0 Antiparkinsoniano @5 04`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 07`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 07`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 07`
C03	`04`	`X`	`FRE`	`@0 Dyskinésie @5 10`
C03	`04`	`X`	`ENG`	`@0 Dyskinesia @5 10`
C03	`04`	`X`	`SPA`	`@0 Disquinesia @5 10`
C03	`05`	`X`	`FRE`	`@0 Toxicité @5 11`
C03	`05`	`X`	`ENG`	`@0 Toxicity @5 11`
C03	`05`	`X`	`SPA`	`@0 Toxicidad @5 11`
C03	`06`	`X`	`FRE`	`@0 Cabergoline @2 NK @2 FR @5 13`
C03	`06`	`X`	`ENG`	`@0 Cabergoline @2 NK @2 FR @5 13`
C03	`06`	`X`	`SPA`	`@0 Cabergolina @2 NK @2 FR @5 13`
C03	`07`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 14`
C03	`07`	`X`	`ENG`	`@0 Dopamine agonist @5 14`
C03	`07`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 14`
C03	`08`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 15`
C03	`08`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 15 @6 «D2» Dopamine receptor`
C03	`08`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 15`
C03	`09`	`X`	`FRE`	`@0 Agoniste @5 16`
C03	`09`	`X`	`ENG`	`@0 Agonist @5 16`
C03	`09`	`X`	`SPA`	`@0 Agonista @5 16`
C03	`10`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`10`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`10`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`11`	`X`	`FRE`	`@0 Chimiothérapie @5 18`
C03	`11`	`X`	`ENG`	`@0 Chemotherapy @5 18`
C03	`11`	`X`	`SPA`	`@0 Quimioterapia @5 18`
C03	`12`	`X`	`FRE`	`@0 Activité biologique @5 19`
C03	`12`	`X`	`ENG`	`@0 Biological activity @5 19`
C03	`12`	`X`	`SPA`	`@0 Actividad biológica @5 19`
C03	`13`	`X`	`FRE`	`@0 Long terme @5 20`
C03	`13`	`X`	`ENG`	`@0 Long term @5 20`
C03	`13`	`X`	`SPA`	`@0 Largo plazo @5 20`
C03	`14`	`X`	`FRE`	`@0 Relation dose réponse @5 21`
C03	`14`	`X`	`ENG`	`@0 Dose activity relation @5 21`
C03	`14`	`X`	`SPA`	`@0 Relación dosis respuesta @5 21`
C03	`15`	`X`	`FRE`	`@0 Animal @5 22`
C03	`15`	`X`	`ENG`	`@0 Animal @5 22`
C03	`15`	`X`	`SPA`	`@0 Animal @5 22`
C03	`16`	`X`	`FRE`	`@0 Ergot dérivé @5 33`
C03	`16`	`X`	`ENG`	`@0 Ergot derivatives @5 33`
C03	`16`	`X`	`SPA`	`@0 Ergot derivado @5 33`
C03	`17`	`X`	`FRE`	`@0 Singe @5 78`
C03	`17`	`X`	`ENG`	`@0 Monkey @5 78`
C03	`17`	`X`	`SPA`	`@0 Mono @5 78`
C03	`18`	`X`	`FRE`	`@0 Voie souscutanée @5 79`
C03	`18`	`X`	`ENG`	`@0 Subcutaneous administration @5 79`
C03	`18`	`X`	`SPA`	`@0 Vía subcutánea @5 79`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 53`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 53`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 53`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 54`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 54`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 54`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 55`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 55`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 55`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 56`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 56`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 56`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 57`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 57`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 57`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 62`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 62`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 62`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 63`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 63`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 63`
C07	`08`	`X`	`FRE`	`@0 Primates @2 NS`
C07	`08`	`X`	`ENG`	`@0 Primates @2 NS`
C07	`08`	`X`	`SPA`	`@0 Primates @2 NS`
C07	`09`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`09`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`09`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`10`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`10`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`10`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 332`

Format Inist (serveur)

NO :	PASCAL 00-0500117 INIST
ET :	Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys
AU :	ABDALLAH HADJ TAHAR; GREGOIRE (Laurent); BANGASSORO (Evelyne); BEDARD (Paul J.)
AF :	Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center/Ste-Foy, Québec/Canada (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 2000; Vol. 23; No. 4; Pp. 195-202; Bibl. 76 ref.
LA :	Anglais
EA :	The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D₂-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D₂ receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.
CC :	002B02U01
FD :	Lévodopa; Antiparkinsonien; Parkinson maladie; Dyskinésie; Toxicité; Cabergoline; Stimulant dopaminergique; Récepteur dopaminergique D2; Agoniste; Traitement; Chimiothérapie; Activité biologique; Long terme; Relation dose réponse; Animal; Ergot dérivé; Singe; Voie souscutanée
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire; Primates; Mammalia; Vertebrata
ED :	Levodopa; Antiparkinson agent; Parkinson disease; Dyskinesia; Toxicity; Cabergoline; Dopamine agonist; D2 Dopamine receptor; Agonist; Treatment; Chemotherapy; Biological activity; Long term; Dose activity relation; Animal; Ergot derivatives; Monkey; Subcutaneous administration
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement; Primates; Mammalia; Vertebrata
SD :	Levodopa; Antiparkinsoniano; Parkinson enfermedad; Disquinesia; Toxicidad; Cabergolina; Estimulante dopaminérgico; Receptor dopaminérgico D2; Agonista; Tratamiento; Quimioterapia; Actividad biológica; Largo plazo; Relación dosis respuesta; Animal; Ergot derivado; Mono; Vía subcutánea
LO :	INIST-16720.354000091364260050
ID :	00-0500117

Links to Exploration step

Pascal:00-0500117

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys</title>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bangassoro, Evelyne" sort="Bangassoro, Evelyne" uniqKey="Bangassoro E" first="Evelyne" last="Bangassoro">Evelyne Bangassoro</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0500117</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0500117 INIST</idno>
<idno type="RBID">Pascal:00-0500117</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys</title>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bangassoro, Evelyne" sort="Bangassoro, Evelyne" uniqKey="Bangassoro E" first="Evelyne" last="Bangassoro">Evelyne Bangassoro</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Animal</term>
<term>Antiparkinson agent</term>
<term>Biological activity</term>
<term>Cabergoline</term>
<term>Chemotherapy</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Dose activity relation</term>
<term>Dyskinesia</term>
<term>Ergot derivatives</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Subcutaneous administration</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Toxicité</term>
<term>Cabergoline</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique D2</term>
<term>Agoniste</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Activité biologique</term>
<term>Long terme</term>
<term>Relation dose réponse</term>
<term>Animal</term>
<term>Ergot dérivé</term>
<term>Singe</term>
<term>Voie souscutanée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D<sub>2</sub>
-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D<sub>2</sub>
 receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ABDALLAH HADJ TAHAR</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GREGOIRE (Laurent)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BANGASSORO (Evelyne)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BEDARD (Paul J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center</s1>
<s2>Ste-Foy, Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>195-202</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000091364260050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>76 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0500117</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D<sub>2</sub>
-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D<sub>2</sub>
 receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Cabergolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>15</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Agonist</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Agonista</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Long terme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Long term</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Relation dose réponse</s0>
<s5>21</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Dose activity relation</s0>
<s5>21</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Relación dosis respuesta</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Animal</s0>
<s5>22</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Animal</s0>
<s5>22</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Animal</s0>
<s5>22</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>33</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>33</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>33</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Singe</s0>
<s5>78</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Monkey</s0>
<s5>78</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Mono</s0>
<s5>78</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Voie souscutanée</s0>
<s5>79</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Subcutaneous administration</s0>
<s5>79</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Vía subcutánea</s0>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>53</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>53</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>54</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>54</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>55</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>55</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>55</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>56</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>56</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>56</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>57</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>57</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>57</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>63</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>332</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0500117 INIST</NO>
<ET>Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys</ET>
<AU>ABDALLAH HADJ TAHAR; GREGOIRE (Laurent); BANGASSORO (Evelyne); BEDARD (Paul J.)</AU>
<AF>Department of Medicine, School of Medicine and Neuroscience Research Unit, Laval University Research Center/Ste-Foy, Québec/Canada (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 2000; Vol. 23; No. 4; Pp. 195-202; Bibl. 76 ref.</SO>
<LA>Anglais</LA>
<EA>The pathophysiology of L-Dopa-induced dyskinesias (LID), a common problem after long-term use of L-dopa in the treatment of Parkinson's disease (PD), is not completely understood. Oscillations in L-Dopa concentrations in the brain are believed to be responsible, at least in part, for their pathogenesis. This study was aimed at verifying whether chronic administration of cabergoline, a long-acting dopamine D<sub>2</sub>
-like receptor agonist, can reverse established LID. Four MPTP-treated cynomolgus monkeys with long-standing and stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa, were used in this study. We compared the antiparkinsonian and dyskinetic responses of L-Dopa methyl ester (62.5 mg and 125 mg), given with benserazide (50 mg) (L-Dopa/benserazide), administered before and after a 6-week period during which the animals were treated only by daily administration of cabergoline (doses ranging from 0.125 to 0.185 mg/kg, subcutaneous). During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment. However, there was no tolerance to its antiparkinsonian effect. L-Dopa/benserazide given 4 days after cabergoline withdrawal produced a significant antiparkinsonian effect, but dyskinesias were dramatically reduced compared to what had been seen before chronic cabergoline treatment. The duration of the L-Dopa response was not increased after chronic administration of cabergoline. Our data suggest that sustained dopamine D<sub>2</sub>
 receptor stimulation could be of value when trying to reduce or to reverse LID in patients with fluctuating advanced PD.</EA>
<CC>002B02U01</CC>
<FD>Lévodopa; Antiparkinsonien; Parkinson maladie; Dyskinésie; Toxicité; Cabergoline; Stimulant dopaminergique; Récepteur dopaminergique D2; Agoniste; Traitement; Chimiothérapie; Activité biologique; Long terme; Relation dose réponse; Animal; Ergot dérivé; Singe; Voie souscutanée</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire; Primates; Mammalia; Vertebrata</FG>
<ED>Levodopa; Antiparkinson agent; Parkinson disease; Dyskinesia; Toxicity; Cabergoline; Dopamine agonist; D2 Dopamine receptor; Agonist; Treatment; Chemotherapy; Biological activity; Long term; Dose activity relation; Animal; Ergot derivatives; Monkey; Subcutaneous administration</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement; Primates; Mammalia; Vertebrata</EG>
<SD>Levodopa; Antiparkinsoniano; Parkinson enfermedad; Disquinesia; Toxicidad; Cabergolina; Estimulante dopaminérgico; Receptor dopaminérgico D2; Agonista; Tratamiento; Quimioterapia; Actividad biológica; Largo plazo; Relación dosis respuesta; Animal; Ergot derivado; Mono; Vía subcutánea</SD>
<LO>INIST-16720.354000091364260050</LO>
<ID>00-0500117</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C66 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0500117
   |texte=   Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri